EXT608 / Extend Biosci - LARVOL DELTA

A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism (clinicaltrials.gov) - P2 | N=35 | Recruiting | Sponsor: Extend Biosciences Inc.

New P2 trial • Endocrine Disorders • Hypoparathyroidism

Preclinical development of EXT608, an investigational parathyroid hormone derivative with extended half-life for the treatment of hypoparathyroidism. (PubMed, JBMR Plus) - "In healthy monkeys, a single dose of PTH(1-34)-vitamin D conjugates elevated serum calcium levels above the normal range for a period of 24-48 h while simultaneously reducing urinary calcium. Therefore, the lead compound, EXT608, is a promising candidate as a therapeutic that can truly mimic the endogenous activity of PTH and warrants further study in patients with hypoparathyroidism."

Journal • Preclinical • Endocrine Disorders • Hypoparathyroidism • Metabolic Disorders • Nephrology • Renal Disease

A Phase 1 Study of EXT608 in Healthy Adults (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Extend Biosciences Inc. | Recruiting ➔ Completed

Trial completion

A Phase 1 Study of EXT608 in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Extend Biosciences Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Phase 1 Study of EXT608 in Healthy Adults (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Extend Biosciences Inc.

New P1 trial